The outpatient management of low-risk febrile patients with neutropenia: risk assessment over the telephone.
OBJECTIVE
The purpose of this retrospective study is to evaluate the feasibility of the risk assessment over the telephone in the outpatient management of low-risk febrile patients with neutropenia.


METHODS
Febrile patients with neutropenia were eligible for outpatient management with oral ciprofloxacin if they demonstrated the following characteristics: resolution of neutropenia expected in <10 days, good performance status, controlled cancer, no symptoms or signs suggesting systemic infection other than fever, and no comorbidity requiring hospitalization. Eligible patients received oral ciprofloxacin (400 mg, three times daily) and were monitored as far as possible by telephone. Risk assessment concerning general condition was carried out over the telephone.


RESULTS
Of the 60 consecutive patients who received neoadjuvant chemotherapy as a phase II trial of docetaxel (60 mg/m(2)) and doxorubicin (50 mg/m(2)) for primary breast cancer, 30 low-risk febrile patients received oral ciprofloxacin. Twenty-seven of these patients (90%) recovered uneventfully without hospitalization and the use of granulocyte colony-stimulating factor. Treatment was considered to have failed in the remaining three (10%) on the account of the need to modify or change their regimens.


CONCLUSIONS
For carefully selected low-risk febrile patients with neutropenia, risk assessment over the telephone may be convenient, and close daily medical scrutiny may be not routinely required in the outpatient.
Mizuno
Toshiro
T
Division of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. tomizuno@clin.medic.mie-u.ac.jp
Katsumata
Noriyuki
N
Mukai
Hirofumi
H
Shimizu
Chikako
C
Ando
Masashi
M
Watanabe
Toru
T
D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy; D017024:Chemotherapy, Adjuvant; D002939:Ciprofloxacin / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D000077143:Docetaxel; D004317:Doxorubicin / Q000009:adverse effects; D005240:Feasibility Studies; D005260:Female; D005334:Fever / Q000188:drug therapy*; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007564:Japan; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009503:Neutropenia / Q000188:drug therapy*; D011994:Recombinant Proteins; D012189:Retrospective Studies; D018570:Risk Assessment; D043823:Taxoids / Q000009:adverse effects; D013689:Telephone; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D011994:Recombinant Proteins; D043823:Taxoids; D016179:Granulocyte Colony-Stimulating Factor; D000077143:Docetaxel; D002939:Ciprofloxacin; D004317:Doxorubicin